The FY23 Defense Appropriations Act provides funding for the Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.
The FY23 Defense Appropriations Act provides funding for the Melanoma Research Program to support innovative, high-impact melanoma research.
The FY23 Defense Appropriations Act provides funding for the Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members, and all women impacted by this disease.
The FY23 Defense Appropriations Act provides funding for the Lung Cancer Research Program to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
The Dan Lewis Foundation for Brain Regeneration Research announced the 2023 DLF Prize. The $15,000 grant will be awarded to an early career scientist in neuroscience, pharmacology, or biotechnology whose research record and future research plans align with one or more of the DLF’s current research priorities.
The FY23 Defense Appropriations Act is anticipated to provide funding for the BCRP to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for service members, veterans, and the general public.
The V Foundation has established a grant program aimed at increasing female representation and female-led innovation in cancer research.
The FY23 Defense Appropriations Act provides funding for the Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer.
FDA’s Oncology Center of Excellence published a Request for Applications for projects focused on applied regulatory science research to understand factors that affect the safety and efficacy of underrepresented populations in oncology therapeutic development.
FDA’s Oncology Center of Excellence published a Request for Applications for projects aimed at developing and implementing new approaches to support drug development for ultra-rare pediatric and adult cancers.
